At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NVCR NovoCure
Closed 06-26 16:00:00 EDT
15.43
+0.38
+2.52%
盘后15.13
-0.30-1.94%
17:59 EDT
High15.63Low14.90Vol3.29M
Open14.91D1 Closing15.05Amplitude4.85%
Mkt Cap1.79BTradable Cap1.49BTotal Shares115.82M
T/O50.69MT/O Rate3.41%Tradable Shares96.66M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Wedbush Initiates a Hold Rating on NovoCure (NVCR)
TIPRANKS  ·  06-23
Wedbush Initiates a Hold Rating on NovoCure (NVCR)
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)
TIPRANKS  ·  06-22
Analysts Are Bullish on These Healthcare Stocks: NovoCure (NVCR), Ocular Therapeutix (OCUL)
Top Midday Decliners
MT Newswires Live  ·  06-19
Top Midday Decliners
Sector Update: Healthcare Stocks Decline Thursday Afternoon
MT Newswires Live  ·  06-19
Sector Update: Healthcare Stocks Decline Thursday Afternoon
NovoCure Down Nearly 18%, On Track for Largest Percent Decrease Since July 2025 -- Data Talk
Dow Jones  ·  06-19
NovoCure Down Nearly 18%, On Track for Largest Percent Decrease Since July 2025 -- Data Talk
Novocure Price Target Cut to $46.00/Share From $48.00 by HC Wainwright & Co.
Dow Jones  ·  06-19
Novocure Price Target Cut to $46.00/Share From $48.00 by HC Wainwright & Co.
BUZZ-U.S. STOCKS ON THE MOVE-Kardigan, Energy companies
Reuters  ·  06-18
BUZZ-U.S. STOCKS ON THE MOVE-Kardigan, Energy companies
Analyst Maintains Buy on NovoCure, Trims Price Target to $46 Amid Shift to New Indications and Stable GBM Franchise
TIPRANKS  ·  06-18
Analyst Maintains Buy on NovoCure, Trims Price Target to $46 Amid Shift to New Indications and Stable GBM Franchise
Novocure price target lowered to $46 from $48 at H.C. Wainwright
TIPRANKS  ·  06-18
Novocure price target lowered to $46 from $48 at H.C. Wainwright
Novocure Limited : H.c. Wainwright Cuts Target Price to $46 From $48
THOMSON REUTERS  ·  06-18
Novocure Limited : H.c. Wainwright Cuts Target Price to $46 From $48
Novocure falls -18.2%
TIPRANKS  ·  06-18
Novocure falls -18.2%
BUZZ-U.S. STOCKS ON THE MOVE-Pfizer, Accenture, Kroger
Reuters  ·  06-18
BUZZ-U.S. STOCKS ON THE MOVE-Pfizer, Accenture, Kroger
Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint
Dow Jones  ·  06-18
Novocure's Late-Stage Trial For Tumor Treatment Misses Primary Endpoint
Top Premarket Decliners
MT Newswires Live  ·  06-18
Top Premarket Decliners
NovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint
MT Newswires Live  ·  06-18
NovoCure Phase 3 Glioblastoma Trial Misses Overall Survival Endpoint
Novocure says Phase 3 TRIDENT trial did not meet primary endpoint
TIPRANKS  ·  06-18
Novocure says Phase 3 TRIDENT trial did not meet primary endpoint
Novocure's cancer treatment fails to meet late-stage trial goal
Reuters  ·  06-18
Novocure's cancer treatment fails to meet late-stage trial goal
Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use
Reuters  ·  06-18
Novocure says Phase 3 TRIDENT glioblastoma trial misses overall survival endpoint for earlier TTFields use
Novocure Announces Topline Data From the Phase 3 Trident Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
THOMSON REUTERS  ·  06-18
Novocure Announces Topline Data From the Phase 3 Trident Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma
Novocure - Early Start Arm Median Overall Survival 17.7 Months VS 17.5 Months in Maintenance Start Arm
THOMSON REUTERS  ·  06-18
Novocure - Early Start Arm Median Overall Survival 17.7 Months VS 17.5 Months in Maintenance Start Arm

Introduction

Company Name.
NovoCure
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.
Issue price:
--